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SUPPLEMENTARY FIGURES 
 
 
 
 
Supplementary Figure 1. Absolute and normalized tonic current amplitudes in TC 
neurons of GAERS and monogenic mutant mice. (a) Comparison of the normalized 
tonic current amplitude in NEC and GAERS for the same cells as in Fig. 1b. (b) 
Comparison of tonic current amplitude in pre–seizure stargazer (stg, P13–15, light 
grey column), lethargic (lh, P13–15, grey column) and tottering (tg, P16–18, dark 
grey column) mice compared to respective control littermates (LIT., white columns) 
of the same age. Number of recorded neurons are as indicated. (c) Comparison of 
normalized tonic current amplitude for the same neurons as in (b). (d) Normalized 
tonic current amplitude in post-seizure stargazer (P19–21), lethargic (P27–30) and 
tottering (P26–28) mice compared to respective control littermates (LIT.) of the same 
age. Number of recorded neurons are the same as indicated in Fig. 1c. * P < 0.05, ** 
P < 0.01, *** P < 0.001. 
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Supplementary Figure 2. Lack of contribution of non–GAT–1–dependent 
mechanisms to enhanced tonic current in GAERS. (a) Comparison of the effects of 
bath application of 0.5 mM TTX, and 5 mM flurazepam on tonic current amplitude in 
NEC and GAERS. Values were normalised to the average tonic current amplitude 
under control conditions. (b) Comparison of the drug–induced tonic current in NEC 
and GAERS following bath application of 100 nM THIP and 10 mM GES. Number of 
recorded neurons are as indicated. 
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Supplementary Figure 3. GAT–1 activity is unaffected in DGGCs of GAERS. (a) 
Representative traces from P18–21 DGGCs of NEC (left) and GAERS (right) in the 
presence of the GAT–1 blocker NO711 (10 mM). Tonic currents were revealed by the 
focal application of 100 mM GBZ (white bars). (b) Comparison of the effect of 
NO711 on tonic current in NEC (white column) and GAERS (black column). Number 
of recorded neurons are as indicated. (c) Comparison of normalized tonic current 
amplitude following application of NO711 for the same neurons as in (b). Values in 
(b) and (c) were not significantly different. 
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Supplementary Figure 4. GAT–1 expression is unaltered in GAERS. (a) Western 
blots (left) and quantitative comparison (right) of the relative levels of GAT–1 in 
cortex and thalamus of GAERS and NEC. (b) Immunohistochemical comparison of 
the expression of GAT–1 in perfusion-fixed thalamus (top) and neocortex (bottom) of 
NEC (left) and GAERS (right). Note the low level of expression in the thalamus 
compared to the cortex, and lack of difference in intensity in both strains. Dotted lines 
indicate the boundary between VB and the nucleus reticularis thalami (NRT). 
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Supplementary Figure 5. The anti–absence drugs ethosuximide and sodium 
valrpoate do not affect tonic current amplitude in GAERS. (a) Effect of 750 mM 
ethosuximide (ETX) and 500 mM sodium valproate (VAL) on tonic current amplitude 
in TC neurons of P18–21 GAERS. Values were normalised to the average tonic 
current amplitude under control conditions.  Number of recorded neurons for each 
drug are as indicated.  
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SUPPLEMENTARY TABLES 
 
 
Supplementary Table 1. Comparison of sIPSC properties in TC neurons of NEC and 
GAERS. Data are mean ± s.e.m. and n = number of recorded neurons. * P < 0.05 and 
** P < 0.01. 
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Supplementary Table 2. Comparison of sIPSC properties in TC neurons of 
stargazer, lethargic and tottering mice, and respective control littermates. Data are 
mean ± s.e.m. and n = number of recorded neurons. 
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Supplementary Table 3. Comparison of sIPSC properties in TC neurons of GAT–1 
KO and d KO mice, and respective wildtype littermates (WT); TC neurons of GAERS 
under control conditions and following intra–thalamic administration of 2 nmol site–1 
missense or 2 nmol site–1 d subunit–specific antisense ODNs; and DGGCs of NEC 
and GAERS under control conditions. Data are mean ± s.e.m. n = number of recorded 
neurons. * P < 0.05. 
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LEGENDS FOR SUPPLEMENTARY MOVIES 1 AND 2 
Supplementary Movie 1. Movie showing the occurrence of absence seizures in a 
normal Wistar rat during the intra–thalamic administration of 200 mM NO711. Note 
the strict time correlation between the behavioural components of the seizures 
(immobility and twitching of the vibrissae) and the appearance of large amplitude 
SWDs in the EEG, as depicted on the oscilloscope. 
 
Supplementary Movie 2. Movie showing the occurrence of a number of absence 
seizures induced by the intra–thalamic administration of 100 mM THIP in a normal 
Wistar rat. The appearance of SWDs in the EGG correlates with the behavioural 
components of the seizures, including immobility, head and neck jerks, and twitching 
of vibrissae. Note the lack of head and neck jerks during the first seizure.  
 
SUPPLEMENTARY RESULTS 
Normalized tonic current amplitude in genetic models of typical absence seizures 
We normalized tonic current amplitude to whole–cell capacitance to determine 
whether increased tonic current was due to changes in the basic cellular properties of 
the TC neurons. No difference in normalized tonic current amplitude between 
GAERS and NEC was observed from P14–16, but at P17 normalized tonic current 
amplitude became significantly larger in GAERS (P < 0.05). This increase was 
sustained in subsequent days (Supplementary Fig. 1a). No difference in normalized 
tonic current amplitude was observed between control littermates and stargazer, 
lethargic and tottering mice at pre–seizure ages (Supplementary Fig. 1c). However, 
normalized tonic current was significantly larger in post–seizure stargazer and 
lethargic (both P < 0.05), but not tottering, mice (Supplementary Fig. 1d), although 
the magnitude of the normalized tonic current in tottering mice was similar to both 
stargazer and lethargic. Importantly, there was no difference in whole–cell 
capacitance between any of the mutant and control strains at any age tested (data not 
shown). 
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Other cellular mechanisms do not contribute to enhanced tonic current in 
GAERS 
Since tonic current in TC neurons is dependent on vesicular GABA release1, 
enhanced tonic current may be caused by increased vesicular GABA. However, 
sIPSC frequency, a measure of action–potential dependent vesicular GABA release, 
was not significantly higher in GAERS compared to NEC at any age tested 
(Supplementary Table 1). Furthermore, miniature IPSC (mIPSC) frequency, 
recorded in the presence of 0.5 mM TTX, was no different between P18–21 GAERS 
and NEC (4.3 ± 0.7 Hz and 4.7 ± 0.9 Hz, respectively). Interestingly, similar sIPSC 
and mIPSC frequencies in each strain indicate that under our experimental conditions 
the majority of vesicular GABA release is quantal. In agreement with this, we saw no 
effect of TTX on tonic current amplitude in either GAERS or NEC (Supplementary 
Fig. 2a). 
 
Mis–expression of sGABAARs in the extrasynaptic membrane might lead to enhanced 
tonic current. Since sGABAARs in TC neurons contain the g2 subunit and are 
susceptible to modulation by benzodiazepines2–4, we compared the effects of the 
benzodiazepine flurazepam (5 mM) in P18–21 GAERS and NEC. Flurazepam had no 
effect on tonic current (Supplementary Fig. 2a), but did increase the weighted decay 
of sIPSCs in both strains (data not shown; both P < 0.05). Thus, sGABAARs are not 
displaced in the extrasynaptic membrane of GAERS. 
 
Increased tonic current could also be caused by overexpression of d subunit–
containing extrasynaptic receptors. Therefore, we compared the effects of the d 
subunit–selective agonist THIP (100 nM) in P18–21 GAERS and NEC. THIP 
increased tonic current significantly in both GAERS and NEC (both P < 0.001). 
However, the additional THIP–induced currents in both strains were remarkably 
similar not only to each other (Supplementary Fig. 2b), but also to that observed in 
normal Wistar rats of comparable age (62.6 ± 11.3 pA) (Fig. 1e). Thus, the number of 
eGABAARs is not different between GAERS and NEC. 
 
Low concentrations of endogenous taurine activate eGABAARs in TC neurons5, 
suggesting that enhanced tonic current could arise due to impaired taurine transport in 
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GAERS. The taurine transporter inhibitor guanidinoethyl sulfonate (GES, 10 mM) 
significantly increased tonic current in P18–21 GAERS and NEC (both P < 0.001). In 
both strains, however, the additional GES–induced currents were similar 
(Supplementary Fig. 2b), indicating that aberrant taurine transport does not 
contribute to enhanced tonic current in GAERS. 
 
Expression and genetic variants of GAT–1 
Impaired GAT–1 activity in GAERS may be caused by reduced GAT–1 expression. 
In western blots, GAT–1 was detected as a ~67 kDa band in both GAERS and NEC, 
but no difference in protein levels were observed in thalamus or cortex 
(Supplementary Fig. 4a). Furthermore, no difference in GAT–1 immunostaining was 
observed in the thalamus or neocortex between GAERS and NEC (Supplementary 
Fig. 4b). 
 
The mutations underlying absence seizures in GAERS are polygenic and unknown6, 
therefore we tested for possible genetic variants in GAT–1. Analysis of cDNA 
sequences derived from GAERS revealed a single, silent nucleotide polymorphism (G 
to A) at position 1109 that appears to represent a strain–dependent difference between 
GAERS and the Brown Norway rat of the Ensembl genomic database. Furthermore, 
no genetic variants were observed in GAT–1 cDNAs from stargazer or lethargic. In 
addition, we tested in cDNAs of GAERS for genetic variants in stargazin and the b4 
Ca2+ channel subunit, the mutated proteins in stargazer and lethargic mice, 
respectively. However, no genetic variants were found. Thus, GAT–1 malfunction is 
not due to reduced expression or genetic variation, and the mutations responsible for 
absence seizures in stargazer and lethargic mice do not occur in GAERS. 
 
SUPPLEMENTARY DISCUSSION 
Tonic GABAA inhibition and absence seizures in tottering mice 
Out of the eight preparations that develop absence seizures (GAERS, stargazer, 
lethargic, tottering, GAT–1 KO, GHB, THIP [systemic or intra–thalamic] and intra–
thalamic NO711), the tottering mice were the only one that did not exhibit enhanced 
tonic GABAA inhibition. Such a high degree of consistency across preparations is 
remarkable, especially given the diverse genetic and pharmacological backgrounds of 
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the different models investigated. Interestingly, tonic current amplitude in tottering 
mice was of similar magnitude to that seen in both stargazer and lethargic mice, thus a 
large tonic current seems to be a feature of the background tottering strain. The effects 
of the inherently large tonic current may only become apparent when combined with 
the tottering mutation. For instance, absence seizures may appear only when the 
inherently large tonic current combines with the selectively compromised excitatory 
rather than inhibitory synaptic transmission that occurs in TC neurons of tottering 
mice7, leading to an overwhelming shift in the balance of excitation and inhibition in 
favour of inhibition. (Interestingly, a similar mechanism may underlie the GHB 
induction of seizures, with the proposed GABABR–dependent facilitation of 
eGABAARs combining with the selective reduction in excitatory neurotransmission in 
the thalamus resulting from the activation of pre–synaptic GABABRs8, leading to an 
overwhelming increase in both phasic and tonic GABAA inhibition). Or, given the 
recent demonstration of recovery of both convulsive and non–convulsive epilepsy 
phenotypes following the crossbreeding of mice, including tottering, with opposing 
epilepsy mutations9, it is possible that the EEG and behavioural effects of a large 
tonic current in control tottering littermates may be effectively masked by other 
mutations. Despite these arguments, however, another possible explanation is that 
thalamic eGABAARs are not important for the generation of seizures in tottering 
mice, and that they arise due to some other cellular pathology, suggesting that 
multiple mechanisms can give rise to the same behavioural abnormalities in different 
absence seizure models. 
 
Aberrant phasic GABAA inhibition in absence seizures and the role of synaptic 
GABAARs in the therapeutic treatment of absence epilepsy 
Our data show that phasic inhibition in TC neurons is largely unaltered in the genetic 
models examined, with the exception of the GAT–1 KO mice where there is an 
apparent gain–of–function in sIPSCs. This is in agreement with previous studies on 
sIPSCs in young GAERS10, in transgenic mice with a mutation (g2R43Q) identified in 
an epileptic human cohort11, and evoked IPSCs in lethargic and tottering mice7. 
However, changes in putative sGABAARs have been demonstrated in an acquired 
model of absence seizures, most notably a reduction of g2 subunit expression12, 
although the functional consequences of this reduction were not examined because 
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IPSCs were not measured. This general lack of change in phasic inhibition apparently 
contradicts the fact that absence epilepsy can be successfully treated by the 
benzodiazepine clonazepam. However, it is has been demonstrated that clonazepam 
has its action in the nucleus reticularis thalami (NRT) rather than sensory thalamic 
nuclei, because it selectively targets GABAARs containing the a3 subunit that are 
present in the NRT but not the VB13–15. An NRT–specific locus of clonazepam action 
is supported by its lack of effect on absence seizures when selectively administered to 
the VB of lethargic mice, whereas intra–NRT administration suppresses seizures16. In 
summary, changes in phasic inhibition in TC neurons are rare in models of absence 
seizures, whereas our findings show that aberrant tonic inhibition is more prevalent. 
Furthermore, sGABAARs in TC neurons are not a current target for therapy, whereas 
those in the NRT are. 
 
Aberrant tonic inhibition in other models of epilepsy 
Our findings are the first to show enhanced eGABAAR function as a common 
mechanism in diverse models of generalized epilepsy, and in the case of GAERS prior 
to the onset of absence seizures. Previous studies have identified aberrant eGABAAR 
function following the induction of temporal lobe epilepsy, but observed changes are 
variable and somewhat contradictory. Thus, after pilocarpine induced status 
epilepticus, tonic GABAA current is either enhanced17 or unaltered18 in DGGCs. 
Furthermore, tonic current is increased in CA1 pyramidal neurons after pilocarpine or 
kainic acid administration, but only in the presence of elevated ambient GABA19, or 
reduced in cultured pyramidal neurons following chronic treatment with kainic acid or 
cyclothiazide20. Interestingly, in cultured hippocampal neurons from mice with a 
GABAAR g2 subunit mutation (R43Q) found in humans with generalized epilepsy 
including absences21, tonic current was reduced, but there was no effect in neurons 
from another g2 subunit (K289M) mutant mouse strain22. Furthermore, a reduction in 
tonic current has been shown in DGGCs of stargazer23. Together with our results, this 
suggests that cell–type specific changes in eGABAAR function can occur in the same 
animal. However, in light of these findings in both stargazer and g2R43Q mice, it is 
important to bear in mind that the hippocampal formation does not participate in the 
generation or maintenance of absence seizures, and that both mouse strains have a 
phenotype more complex than absence seizures alone. 
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Changes in GABAAR–mediated inhibition have also been documented in two mouse 
models of autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE)24, a partial 
epilepsy syndrome that arises due to mutations in nicotinic ACh receptor subunit 
genes25. In ADNFLE mice, seizures were suppressed by administration of the 
GABAAR antagonist picrotoxin, whereas there was negligible effect in WT mice. In 
cortical neurons, sIPSCs were no different between mutant mice and WTs, but 
application of nicotine caused a massive increase in sIPSC frequency and amplitude 
in the mutants that was not apparent in WTs24. Although it was not examined, one 
might expect a concomitant increase in tonic inhibition in response to the nicotine–
induced increase in vesicular GABA release. 
 
Aberrant GAT–1 function has also previously been described in models of convulsive 
epilepsy. In seizure prone rats, audiogenic seizures induced a large reduction in GAT–
1 mRNA expression in hippocampus and cortex26. Kainic acid–induced seizures 
compromised GAT–1 function in hippocampus27, and reduced immunoreactivity of 
neocortical GAT–1 was observed after pilocarpine administrations. Similarly, GAT–1 
immunoreactivity in the dentate gyrus was reduced following kindling evoked 
seizures28. Loss of GAT–1 has been observed in patients with temporal lobe 
epilepsy27,29. However, our data show that impaired GAT–1 function need not 
necessarily correlate with loss of GAT–1 expression to cause epileptic phenotypes. 
 
A possible role for thalamic eGABAARs in absence seizures 
Given our current knowledge of thalamo–cortical interactions during absence 
episodes30,31, we suggest the following role of enhanced tonic GABAA inhibition in 
SWDs. Seizures arise due to paroxysmal development of normal 5–9 Hz oscillations 
in a discrete somatosensory cortical initiation site32–34, which powerfully excites the 
GABAergic neurons of the NRT35. These neurons respond by generating low–
threshold Ca2+ potential–mediated bursts of action potentials on every cycle of the 
SWD, resulting in barrages of IPSPs in TC neurons which override the cortical 
excitation35,36. Concomitantly, ambient GABA levels increase37 due to reduced 
GABA uptake by GAT–1, enhancing eGABAAR function directly, and indirectly by 
GABABR–dependent facilitation. Enhanced tonic inhibition, in combination with 
classical post-synaptic GABABR activation (see below), persistently hyperpolarises 
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the TC neurons and increases membrane conductance3, reducing the action potential 
output of the TC neurons, with low threshold Ca2+ potential–mediated bursts of action 
potentials rarely occurring36,38,39. Furthermore, the responsiveness of TC neurons to 
excitatory, sensory synaptic input is reduced, ‘gating’ information flow through the 
thalamus and causing behavioural arrest. The rhythmic IPSP barrages entrain TC 
neuron output to cycles of the SWD, providing a sparse but synchronised input to the 
cortex and maintaining paroxysmal activity in the thalamo–cortical network. Whilst 
our hypothesis focuses on the role of enhanced tonic inhibition in the thalamus, we do 
not exclude the possibility that other cellular alterations in the thalamo–cortical 
network, perhaps including increased tonic inhibition in the cortex, may contribute to 
seizures, and that different cellular mechanisms may underlie absence seizures in 
different models. Furthermore our hypothesis supports the observation that although 
SWDs are initiated in the cortex, intact thalamo–cortical networks are required for the 
full behavioural expression of absence seizures34.  
 
GABAB receptors and absence seizures 
Our data highlight a potentially novel contribution of GABABRs to absence seizures, 
a GABABR–dependent facilitation of eGABAAR function. Whilst the mechanism(s) 
underlying this effect have yet to be determined, they suggest that the GABABR 
sensitivity of absence seizures is due, at least in part, to this novel receptor–receptor 
interaction. Indeed the sensitivity of SWDs to GABABR modulation is a defining 
characteristic of absence seizures, and previous studies in both genetic and 
pharmacological models of absence seizures have shown that systemic or intra–
thalamic administration of GABABR agonists are capable of inducing or exacerbating 
SWDs, whereas GABABR antagonists suppress them40–42. In addition, absence 
seizures can be induced following intra–VB administration of GHB43, a weak agonist 
at GABABRs, although the contribution of a putative GHB receptor cannot be 
discounted44. The apparent GABABR mediated augmentation of eGABAAR function 
occurs despite the reduction in GABA release and ambient GABA following 
activation of pre-synaptic GABABRs45,46.  
 
The novel GABABR–eGABAAR interaction does not detract from the classical post-
synaptic GABABR effects, i.e. the opening of G protein–coupled inwardly rectifying 
K+ channels. In addition to barrages of IPSPs arising from GABAergic NRT neurons,  
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TC neurons exhibit a persistent hyperpolarization during SWDs36,47. Furthermore, 
eGABAAR and post–synaptic GABABR activation leads to an increase in membrane 
conductance3,48. Together, these effects cause TC neurons to generate action 
potentials only rarely during SWDs, but with sufficient synchrony to drive the cortex 
and maintain seizures36,38,47. Our data suggest that the combined effects of eGABAAR 
activation, post–synaptic GABABR activation, and GABABR–dependent facilitation 
of eGABAARs is responsible for the membrane hyperpolarization and increase in 
membrane conductance. Although one would predict that hyperpolarization of TC 
neurons should initiate low–threshold Ca2+ potential–dependent burst firing49, this is 
apparently not case, and, as described above, TC neurons rarely fire any action 
potentials, let alone bursts, during a SWD36,38,47. We suggest that the increase in 
membrane conductance has greater impact on the responsiveness of TC neurons than 
the hyperpolarization, effectively preventing the generation of low–threshold Ca2+ 
potential–dependent bursts and making the TC neurons unresponsive to synaptic 
input. Thus, the silencing of TC neurons during most of the SWD effectively ‘gates’ 
the thalamus, and probably underlies the behavioural arrest characteristic of absence 
seizures. This is in contrast to an in vitro model of thalamic hyperexcitability elicited 
by GABAAR antagonists where GABABR activation drives burst firing of TC neurons 
on every cycle of the paroxysmal activity50–52. However, absence seizures are 
suppressed by intra–VB administration of GABAAR antagonists not exacerbated, at 
least in GAERS40. Despite the intimate involvement of GABABRs in seizure genesis, 
they ultimately do not appear to be a target for therapeutic intervention, but may play 
a role in exacerbation of absence seizures by anti–convulsants such as tiagabine and 
vigabatrin. In any case, we have potentially identified the cellular mechanisms by 
which both tiagabine and vigabatrin exacerbate absence seizures. 
 
SUPPLEMENTARY METHODS 
In vitro slice preparation and whole–cell patch clamp recordings 
Slice preparation and whole–cell patch clamp recordings were performed as described 
previously3. Briefly, male and female Wistars, GAERS, NEC, stargazer, lethargic, 
tottering and respective control littermates, and GAT–1 and d subunit KO and 
respective WT littermates, of the relevant postnatal ages (see text for details) were 
anaesthetised with isoflurane and decapitated, in accordance with the United 
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Kingdom Animals (Scientific Procedures) Act 1986 and associated procedures. The 
brains were rapidly removed, and 300 mm thick horizontal sections containing either 
the thalamus or hippocampus were cut, using a vibroslicer (HM 650 V, Microm 
International, Walldorf, Germany), in cold (<4 ºC), continuously oxygenated (95% 
O2: 5% CO2) artificial CSF (aCSF) containing (in mM): NaCl 85, NaHCO3 26, MgCl2 
2, CaCl2 2, KCl 2.5, NaH2PO4 1.25, glucose 10, sucrose 73.6, indomethacin 0.045, 
and kynurenic acid 3. Indomethacin and kynurenic acid were included to improve 
slice viability3. Slices were stored in an oxygenated incubation chamber containing 
the above aCSF, but without indomethacin and kynurenic acid, for 15–20 mins before 
the aCSF was gradually replaced with aCSF containing (in mM): NaCl 126, NaHCO3 
26, MgCl2 2, CaCl2 2, KCl 2.5, NaH2PO4 1.25 and glucose 10. Slices were left for at 
least 1 hr before being transferred to the recording chamber where they were 
continuously perfused (1.5 ml min–1) with warmed (33 ± 1 ºC), oxygenated aCSF 
containing (in mM): NaCl 126, NaHCO3 26, MgCl2 1, CaCl2 2, KCl 2.5, NaH2PO4 
1.25, glucose 10 and kynurenic acid 3. Kynurenic acid was used in the recording 
medium to isolate GABAAR currents. Experiments utilising GHB and THIP in Wistar 
rats in vitro were performed in the presence of TTX. 
 
TC neurons of the VB, and DGGCs of the hippocampal formation, were visualised 
using a Nikon microscope (Eclipse E600FN or FN1, Tokyo, Japan) equipped with a 
40´ immersion lens and a video camera (Hamamatsu, Hamamatsu City, Japan). 
Whole cell patch clamp recordings were made from neurons held at –70 mV using 
pipettes (resistance 2-4 MW) containing (in mM): CsCl 130, MgCl2 2, Mg-ATP 4, Na-
GTP 0.3, Na-HEPES 10 and EGTA 0.1, pH 7.25–7.30, osmolality ~290 mOsm. 
Pipettes were attached to the headstage of either a Multiclamp 700B preamplifier, 
controlled by Multiclamp Commander software, or an Axopatch 200A preamplifier 
(Molecular Devices, Sunnyvale, CA, USA). Data were discarded if the series 
resistance changed by >30%. Experimental data were digitized at 20 kHz (Digidata 
1322, Molecular Devices), acquired using pClamp 9.0 software (Molecular Devices), 
and stored on a personal computer.  
 
Data were filtered at 3 kHz and converted to an ASCII format for analysis using 
LabView based software (National Instruments, Austin, TX, USA)3. The presence of 
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a tonic GABAA current was determined using a high concentration of the GABAAR 
antagonist gabazine (GBZ). Briefly, tonic currents were observed as an outward shift 
in baseline current following focal, or in some cases bath, application of 100 mM 
GBZ, since the holding potential was –70 mV and the reversal potential of Cl– ~0 
mV. To measure tonic current amplitude, 5 ms epochs of baseline current were 
sampled every 100 ms, and those epochs that fell on IPSCs discarded. The average 
baseline current was then calculated for two 5 s periods prior to (i and ii), and one 
after (iii), GBZ application. The background ‘drift’ of the baseline current was 
calculated as the difference between the two pre–GBZ periods (ii–i), and the GBZ–
dependent ‘shift’ due to block of the tonic current as the difference between the 
second pre–GBZ period and the post–GBZ period (iii–ii)3. A tonic current was 
presumed to be present for a given neuron if the post–GBZ shift was twice the 
standard deviation of the pre–GBZ drift. In some instances, tonic current amplitude 
was normalised to whole–cell capacitance, which was calculated from small (5 mV) 
voltage steps before and after experiments. For analysis of IPSCs, populations of 
individual IPSCs were averaged, and the peak amplitude, charge transfer (the integral 
of the average IPSC), weighted decay time constant (integral of the average IPSC 
divided by peak amplitude), frequency, and total current (charge transfer X 
frequency) measured3. Tonic current amplitude and IPSC properties were compared 
between strains in different populations of recorded neurons. Similarly, the actions of 
bath applied drugs on tonic current amplitude and IPSC properties were measured in a 
different population of neurons and then compared to the population of control 
neurons3, except for THIP where control and drug action were measured in the same 
cell. Data from the THIP experiments was analysed by measuring 5 ms epochs of 
baseline current every 100 ms for three 20 s periods, one prior to wash–on of THIP, 
one during THIP application, and one following focal application of GBZ. The effects 
of THIP alone and THIP and GBZ together were then calculated relative to the 
control period. 
 
GAT–1 western blot analysis 
Young adult GAERS and NEC (three each) were killed by cervical dislocation and 
samples of the cerebral cortex and thalamus rapidly dissected and frozen on dry ice. 
Total protein was extracted and subjected to western blot analysis using standard 
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procedures53. The primary antibodies used were the GAT–1–specific antibody 
AB1570W (Chemicon, Millipore Corporation, Billerica, MA, U.S.A.), and the 
GAPDH–specific antibody ab9485 (Abcam Ltd., Cambridge, U.K.). Protein bands 
were detected using enhanced chemiluminescence (ECL plus, Amersham/GE 
Healthcare UK, Little Chalfont, Bucks., U.K.) and quantitated by densitometry 
(ImagequantTM 3.0, Amersham/GE). Levels of GAT–1 protein were corrected for 
(extraction and loading) variation against the equivalent GAPDH protein band. 
 
Immunocytochemistry of GAT–1 
Male GAERS and NEC (two each, P18–21) were anaesthetised with sodium 
pentobarbital in accordance with the UK Animals (Scientific Procedures) Act 1986 
and associated procedures, and transcardially perfused initially with phosphate–
buffered saline (PBS, 0.1 M) followed by 4% paraformaldehyde in PBS for 10 mins. 
Brains were removed, extensively rinsed with PBS containing 0.2% Tween 20, and 
coronal sections (50–60 mm) cut on a vibrotome. Sections were incubated in 3% 
normal goat serum for 1.5 hrs, followed by incubation in rabbit GAT–1–specific 
antibody (1:600; ab1570, Chemicon) for 2.5 hrs at room temperature, and then 
overnight at 4 ºC. On the following day, sections were incubated in the secondary 
antibody (biotinylated goat anti–rabbit, 1:200; Vector Laboratories, Burlingame, CA, 
U.S.A.) for 2.5 hrs at room temperature, and staining visualised using the avidin–
biotin–horseradish peroxidise complex procedure (Vecstatin ABC Elite Kit, Vector 
Laboratories). Peroxidase enzyme activity was revealed with 3,3’–diaminobenzidine 
tetrahydrochloride as chromogen and 0.003% H2O2 as substrate. The enzyme reaction 
lasted for 5 mins. 
 
cDNA cloning and sequencing 
Young adult GAERS, stargazer and lethargic animals (one each) were killed by 
cervical dislocation and samples of the cerebellum and thalamus rapidly dissected and 
frozen on dry ice. Total RNA was extracted and cDNA clones of the GAT–1 coding 
sequence, and the stargazin and b4 Ca2+ channel subunit coding sequences for 
GAERS, were obtained using standard RT–PCR procedures as described54. PCR 
primer sequences were derived from Ensembl transcripts 
(http://www.ensembl.org/index.html). Each coding sequence was cloned as multiple 
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fragments of 400–700 bp and sequenced by the DNA Sequencing Core Laboratory in 
the Cardiff School of Biosciences (http://watson-bios.grid.cf.ac.uk/seq/default.php). 
At least two individual clones were sequenced for each fragment and then compared 
with database mRNA sequences (Ensembl, NCBI; http://www.ncbi.nlm.nih.gov). 
 
EEG recordings and reverse microdialysis in behaving animals 
All surgical procedures were performed in accordance with the UK Animals 
(Scientific Procedures) Act 1986 and associated procedures. Male and female GAT–1 
KO (25–35 g, 6–7 months of age), d KO and WT mice (25–35 g, 6–12 months of 
age), male Wistar rats (250–300 g, >13 weeks of age), and male GAERS (250–350 g, 
6–12 months of age) were anaesthetised with a mixture of isoflurane and N2O. In 
Wistar and GAERS animals, six screw electrodes were placed bilaterally over the 
frontal cortex, parietal cortex and cerebellum, whilst in KO and WT mice only four 
screws, bilaterally over the parietal cortex and cerebellum, were implanted. Mice 
underwent no further surgery. 
 
For reverse microdialysis experiments in Wistars two guide cannulae were implanted 
over the VB thalamus and permanently fixed to the skull with methylacrylic cement. 
The position of cannulae was checked post hoc (Fig. 5d) and data from animals with 
incorrectly positioned cannulae were not included for further analysis. After one week 
of recovery, two microdialysis probes (CMA/12, 2 mm length and 500 mm outer 
diameter; Carnegie Medicin, Stockholm, Sweden) connected to a two-channel liquid 
swivel (Carnegie Medicin) were inserted down the guide cannulae to a depth 2 mm 
below the end of the cannulae. 
 
For anti– and missense ODN experiments in GAERS, cannulae were implanted and 
ODNs injected after one week of recovery. To determine the spread of injected 
ODNs, we used a biotinylated antisense ODN and staining was visualised using the 
avidin–biotin–horseradish peroxidase complex procedure (Fig. 5d). For in vitro 
experiments measuring tonic current amplitude after ODN injection, P28–32 GAERS 
were implanted with guide cannulae only, ODNs injected 2 d after surgery, and 
thalamic slices prepared 22–26 hrs after injection, as above.  
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During experiments, all animals were transferred to the recording cage, and EEG 
recordings made using a Neurolog (Digitimer Ltd, Welwyn Garden City, U.K.) or 
Plexon (model REC/64; Dallas, Texas, U.S.A.) amplifier. Data were analysed using 
pClamp 9.0 (Molecular Devices) or Plexon software, respectively. 
 
In GAT–1 KO mice, spontaneous SWDs were recorded for a period of 1 hr. Seizures 
were quantified as the time spent in seizure during 15 min periods. The effect of ETX 
was tested by i.p. injection of 200 mg kg–1 in a volume of 1 ml kg–1. 
 
In d KO mice and WT littermates, control EEG recordings were made for 15 mins 
prior to systemic injection of GBL (50 mg kg–1 i.p.) and the effects of GBL recorded 
for 1 hr. Seizures were quantified as the time spent in seizure during 15 min periods, 
and the effect of ETX was tested by i.p. injection of 200 mg kg–1 in a volume of 1 ml 
kg–1. 
 
In Wistars implanted with reverse microdialysis probes, experiments consisted of 
three stages. Firstly, a control period (30 mins) was recorded without probes. 
Secondly, a period of 20 mins was recorded with probes infusing aCSF (1 ml min–1) 
containing (in mM): 147 Na+, 2.7 K+, 1 Mg2+, 1.2 Ca2+ and 154.1 Cl-, adjusted to pH 
7.4 with 2 mM sodium phosphate buffer. Thirdly, a period of 120 mins was recorded 
with probes infusing either aCSF alone or aCSF containing NO711 (200 mM) or THIP 
(30–100 mM). A technical drawback of reverse microdialysis is that it reduces the 
effective concentration of administered drug to =10% (ref. 55). Therefore the final 
concentration of NO711 was likely to be =20 mM, i.e. still selective for GAT–1 (ref. 
56), and the final concentration of THIP was likely to be =7–10 mM, i.e. still selective 
for eGABAARs57. Seizures were quantified as the time spent in seizure during 20 min 
periods, and the total number of SWDs was also calculated. The effects of ETX were 
tested by i.p. injection of 100 mg kg–1 in a volume of 1 ml kg–1. 
 
For anti– and missense experiments in GAERS, control recordings were made for 1 hr 
prior to the injection of ODNs, and experiments started 1 d after injection. Seizures 
were quantified as the time spent in seizure during 1 hr periods and normalized to the 
control recordings. The total number of SWDs was also calculated. 
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During the recording session, all animals were gently stimulated to prevent them 
falling asleep if required, and video monitored to record the behavioural components 
of absence seizures.  
 
Drug effects were assessed by repeated measures ANOVA with post–hoc Tukey HSD 
when significant differences were found (P < 0.05). The effects of ETX on GBL–, 
NO711– and THIP–induced seizures were compared using Student’s paired t–test (P 
< 0.05).  
 
Sources of animals, and genotyping of mutant mice 
Colonies of GAERS and NEC were maintained at the School of Biosciences, Cardiff 
University. Breeding pairs of stargazer, lethargic, tottering and d KO mice were 
obtained from The Jackson Laboratory (Bar Harbor, Maine, U.S.A.), GAT–1 KO 
mice from the Mutant Mouse Regional Resource Center (University of California, 
Davis, U.S.A.), and colonies initiated at the School of Biosciences. Wistar rats were 
obtained from Harlan U.K. Ltd (Bicester, Oxon, U.K.). 
 
Heterozygous breeding pairs of stargazer, lethargic, tottering, GAT–1 KO and d 
subunit KO mice were used to generate WT, heterozygous and mutant offspring. For 
the majority of experiments, stargazer, lethargic and tottering mutant mice were 
identified by their ataxic phenotypes58 and compared to control littermates, i.e. WT 
and heterozygous mice since the stargazer, lethargic and tottering mutations are 
recessive. For experiments in pre–seizure stargazer, lethargic and tottering mice, 
animals could not be identified by phenotype, therefore conventional genotyping 
protocols involving PCR amplification of genomic DNA were used. The 
oligonucleotide primers used to identify stargazer mice were: STAR–3 5’–ACT GTC 
ACT CTA TCT GGA ATC–3’, LTR–5 5’–GAG CAA GCA GGT TTC AGG C–3’, 
LTR–3 5’–GCC TTG ATC AGA GTA ACT GTC–3’ and STAR–5 5’–CAT TTC 
CTG TCT CAT CCT TTG–3’, giving rise to bands of 600 bp in WT, 600, 300 and 
400 bp in heterozygous, and 300 and 400 bp in stargazer mice. The primers used to 
identify lethargic mice were: Leth–5 5’–AAA TGG TAT CAG GAA CAT TCC GAG 
C–3’ and Leth–3 5’–CAA ACC AGT GAA AGC GTT AGC AAG C–3’ giving rise 
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to bands of 75 bp in WT, 75 and 79 bp in heterozygous and 79 bp in lethargic mice. 
The primers used to identify tottering mice were: IMR 1949 5’–AAC CTG GTT GTC 
TCC CTC CT–3’, IMR 1950 5’–TGT CGA AGT TGG TGG GCG–3’ and IMR 1951 
5’–TGT CGA AGT TGG GCA–3’ giving rise to a band of 665 bp in WT and 
heterozygous mice when IMRs 1949 and 1950 were combined, and in heterozygous 
and tottering mice when IMRs 1949 and 1951 were combined. Although GAT–1 KO 
mice have a phenotype that includes ataxia and tremor59,60, we genotyped animals in 
order to identify heterozygous and WT littermates, since the GAT–1 mutation is not 
recessive. The primers used were: mGAT1 17399–430 5’–GAC ATT TGG CTT ACT 
AGT GAG GAA ACA AGA GC–3’, mGAT1 17830–799 5’–GCT AAG GGG CCT 
CTA CGG AAG CCT CCA GAG GC–3’, and GFP37 9955–64 5’–CCA TCT AAT 
TCA ACA AGA ATT GGG ACA ACT CC–3’ giving rise to bands of 245 bp in 
GAT–1 KO, 245 and 430 bp in heterozygous, and 430 bp in WT mice. Since d 
subunit KO mice exhibit no discernible gross phenotype61,62, we used genotyping 
protocols to identify all offspring. The primers used were: DF 5’–ATG ACT GTG 
TTC CTG CAT CA–3’, DR 5’–AGC CCC TCC CTG AAA GCT AG–3’, and NCR 
5’–TTG TCT GTT GTG CCC AGT CA–3’, giving bands of 350 bp in WT, 550 and 
1450 bp in d KO, and 350, 550 and 1450 bp in heterozygous mice. In experiments, 
GAT–1 and d KO animals were compared to WT littermates only. 
 
GABAAR d subunit antisense and missense ODNs 
The rat d subunit–specific antisense ODN was based on that previously used in the 
mouse63, and did not show any significant homology to any other sequence in 
GenBank. The sequence was: CGT TTA TAC CTT ATG TGG TA and differed from 
that described for the mouse by a single base, as dictated by the cDNA sequence 
(accession number NM_017289). A missense ODN of identical length was used, and 
also based on that previously described63, with no significant homology to any other 
sequence in GenBank. The missense sequence was: ATG GTA TAT TCC ATG TTT 
GC. For localization of injected ODN spread (Fig. 5d) a 3’ biotin–modified antisense 
ODN, with the same sequence as above, was used. Antisense and missense ODNs 
were obtained from Sigma-Genosys Ltd (Cambridge, U.K.). 
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Sources of drugs 
Drugs were obtained from the following sources: kynurenic acid, 4,5,6,7–
tetrahydroisoxazolo–[5,4–C]pyridine–3–ol (THIP), g–hydroxybutyric acid (GHB), 1–
(2–[([diphenylmethylene]imino)–oxy]ethyl)–1,2,5,6–tetrahydro–3–pyri–
dinecarboxylic acid hydrochloride (NO711), 7–chloro-1–(diethylamino)ethyl–5–(2–
fluorophenyl)–3H–1,4–benzodiazepin–2(1H)–one (flurazepam), g–butyrolactone 
(GBL), 2–ethyl–2–methylsuccinimide (ethosuximide), sodium 2–propylpentanoate 
(sodium valproate), and 3,3’–diaminobenzidine tetrahydrochloride from Sigma–
Aldrich (Poole, Dorset, U.K.); 6–imino–3–(4–methoxyphenyl)–1–(6H)–
pyridazinebutanoic acid hydrobromide (gabazine), (2S)–3–[[(1S)–1–(3,4–
dichlorophenyl)ethyl]amino–2–hydroxypropyl]–(phenylmethyl) phosphinic acid 
(CGP55845), tetrodotoxin (TTX), 1–[2[tris(methoxyphenyl)methoxy]ethyl]–(S)–3–
piperidinecarboxylic acid ((S)–SNAP5114) and 6,7,8,9–tetrahydro–5–hydroxy–5H–
benzocyclohept–6–ylideneacetic acid (NCS–382) from Tocris Bioscience (Bristol, 
U.K.); guanidinoethyl sulfonate (GES) from Toronto Research Chemicals Inc. (North 
York, ON, Canada). All drugs were dissolved directly in aCSF, with the exception of 
CGP55845 and SNAP5114 which were initially dissolved in DMSO before addition 
to the aCSF. For in vitro experiments NO711 was dissolved in DMSO, for reverse 
microdialysis experiments in aCSF. 
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